Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 – Submission of Matters to a Vote of Security Holders

The 2017 Annual Meeting of Shareholders (the Annual Meeting) of
Synergy Pharmaceuticals Inc. (the Company) was held on June27,
2017. At the Annual Meeting, the shareholders voted on the
following four (4)proposals and cast their votes as described
below.

Proposal 1 Election of Directors

The following seven (7)individuals were elected as directors, to
serve until the 2018 Annual Meeting of Shareholders or their
successors are elected and qualified with the following votes:

Proposal 2 Approval of Amendment to Second Amended and
Restated Certificate of Incorporation

The shareholders approved the amendment to the Companys Second
Amended and Restated Certificate of Incorporation, as amended,
increasing the number of shares of common stock authorized for
issuance from 350,000,000 to 400,000,000 based on the votes
listed below:

Proposal 3 Approval of 2017 Equity Incentive Plan

The shareholders approved the Synergy Pharmaceuticals Inc. 2017
Equity Incentive Plan based on the votes listed below:

Proposal 4 Ratification of the appointment of BDO USA, LLP

The shareholders ratified and approved the appointment of BDO
USA, LLP as the Companys independent registered public accounting
firm for the fiscal year ending December31, 2017 based on the
votes listed below:

Each of the items considered at the Annual Meeting is described
in further detail in the Definitive Proxy Statement on Schedule
14A filed with the Securities and Exchange Commission on April28,
2017. No item other than the four items addressed above and
described in the Definitive Proxy Statement was submitted at the
Annual Meeting for shareholder action.

About Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company’s uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.